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Abstract
Background: PARP inhibitors (PARPi) have recently been approved for various malignancies based on the results of
several clinical trials. However, these trials have mostly recruited patients with germline BRCA mutations, and it is
unclear whether PARPi have similar efficacy in patients with somatic BRCA mutations. Our study aimed to determine
the efficacy of PARPi in patients with somatic BRCA mutations.
Methods: We performed a meta-analysis comparing overall response rate to PARPi in patients harboring somatic
versus germline BRCA mutations. We looked at studies including somatic and germline mutations in BRCA patients
that received PARPi.
Results: After screening and removing duplicates, 18 studies met our criteria for including both somatic and germline
BRCA mutations. Only 8 studies reported response rates for both somatic and germline BRCA mutations.
In those studies, 24 out of 43 patients with somatic BRCA mutations (55.8%), and 69 out of 157 (43.9%) patients with
germline BRCA patients had a response to therapy to PARPi. This difference was not statistically significant (p = 0.399).
In all five studies that reported progression-free survival, there was no obvious difference in outcomes between
somatic versus germline BRCA patients, however a precise statistical analysis could not be performed.
Conclusion: Our meta-analysis and systematic review of the literature indicates similar response rates of PARPi therapy
in patients with somatic and germline BRCA mutations. Investigation of use of PARPi therapy in a broader patient
population, and the inclusion of somatic BRCA mutations in further clinical trials is paramount in improving therapeutic
options for our patients.
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Background
Since their discovery in 1994 and 1995 respectively,
there has been significant clinical interest in the tumor
suppressor genes BRCA1 and BRCA2, with particular
focus in recent years on targeted therapies for patients
with BRCA mutated cancers. The BRCA1-encoded pro-
tein is an important DNA damage response protein that
interacts with multiple sensor and effector proteins in
the DNA repair pathways, and is also involved directly
in the repair of double-stranded DNA breaks, and
BRCA2 is primarily involved in facilitating homologous
recombination repair of DNA damage [1, 2]. Defects in
function therefore lead to dysfunctional chromosomal
rearrangement and cellular replication. Deleterious
germline mutations in the BRCA1 protein have been
found to significantly increase the risk of breast cancer
and ovarian cancer, up to 72 and 44% respectively by
age 80, as well as increased risk of many gastrointestinal,
pancreatic and prostate cancers [3, 4]. BRCA2 deleteri-
ous mutations confer a similar risk of breast and ovarian
cancer, as well as pancreatic cancer, prostate cancer,
stomach cancer, and melanoma as well [3, 5]. Somatic
BRCA mutations which are present only in the tumor
cells, have been reported to be up to 15–30% of all
BRCA1/2 mutations, and can be found in various malig-
nancies, such as 3% of breast cancer cases, and over 12%
of advanced prostate cancer patients [6–10].
Poly(ADP-ribose) polymerase (PARP) is a nuclear
protein that is activated by breaks in DNA single
strands, which then further recruits DNA repair pro-
teins with synthesis of poly(ADP-ribose) chains [11].
A class of medications, the PARP inhibitors (PARPi),
were developed to specifically target the DNA repair
pathways involved with PARP1, as well as the other
PARP enzymes. Use of PARPi was found to increase
apoptosis of BRCA1 and BRCA2 mutated cells, due
to a combination of increased DNA lesions and in-
ability for defective BRCA1 and BRCA2 products to
repair the DNA, an example of the genetic concept
called synthetic lethality [12, 13]. Multiple PARPi
have since been FDA approved for advanced ovarian
cancer and/or breast cancer, such as olaparib in 2014,
rucaparib in 2016, niraparib in 2017, and talazoparib
in 2018 [14]. The study of PARPi has been mostly
limited to patients with germline BRCA mutations
and hence there is a lack of data comparing response
rates to PARPi in patients with somatic versus germ-
line BRCA mutations. Furthermore, there is a concern
that somatic BRCA mutations detected in tumor tis-
sue, may be passenger mutations instead of driver
mutations, and thus targeting it may not be of utility
[15]. In order to better ascertain this, we performed a
meta-analysis comparing overall response rate to
PARPi in patients harboring a somatic versus
germline BRCA mutation. We looked at all published
studies including somatic and germline mutations in
BRCA patients that received PARPi.
Methods
Search strategy
The search strategy was developed and verified by two
authors (W.L-S and G.M). The following databases were
queried for the purpose of this manuscript: PubMed/
Medline, Embase, Cochrane Register of Controlled Tri-
als, and Web of Science Core Collection from inception
through November 15th 2019. Medical subject headings
and keyword synonyms for the concepts of Somatic mu-
tations, germline mutations, and PARPi were developed
on PubMed and translated for querying other databases.
The detailed search strategy for Embase is presented as
example in supplementary Table 1. Relevant articles
were initially screened based on title and abstracts. The
articles were finalized for the purpose of this review by
two reviewers (G.M and A.K) and the discrepancy was
resolved by a third reviewer (M.A).
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines were adhered to for
the purpose of this manuscript [16]. Figure 1 shows
search strategy and findings, screening, study selection
and exclusion and final analysis.
Study definitions
Somatic BRCA mutations were defined as either a
BRCA1 or BRCA2 mutations present only in the tumor
tissue. Germline BRCA mutations were defined as either
a BRCA1 or BRCA2 mutation that was present on germ
cells, identified by the study authors through genetic
testing of non-tumor tissue, such as a blood test. Re-
sponse rate was defined as a reduction in tumor size per
the respective studies using RECIST criteria whenever
applicable [17]. Progression-free survival was defined as
per the respective studies from the time of initiation of
treatment to the onset of progression or death from any
cause, defined as per RECIST criteria, whenever applic-
able [17].
Inclusion and exclusion criteria
Our study inclusion criteria were all studies (includ-
ing retrospective studies and clinical trials) that re-
ported use of PARPi in patients with both somatic
and germline BRCA patients. Our search strategy was
limited to randomized controlled trials (RCT) and co-
hort studies only. We excluded all other studies in-
cluding single arm studies, case reports, small case
series, editorials, review articles, and perspectives. Our
search was not restricted to language or dates. We
also included abstracts for the purpose of this review.
We only included studies that reported on results for
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both somatic and germline BRCA mutations in our
quantitative analysis, and hence studies that included
just patients with somatic mutations, or just germline
mutations were not included.
Data collection
The underlying cancer type, phase/type of study and
number/responses of patients with somatic and germline
mutations were extracted where applicable. Type of
treatment regimen and data of progression-free survival
(PFS) was extracted. The data extraction was performed
by two reviewers (G.M. and M.A.) and cross verified to
resolve any discrepancy.
Primary and secondary outcomes
Our primary objective was to compare the overall re-
sponse rate (ORR) with PARPi therapy for patients har-
boring somatic versus germline BRCA mutations. We
also aimed to assess progression-free survival (PFS) data
in patients with somatic versus germline BRCA
mutations.
Data synthesis and statistical analysis
We extracted data using Microsoft Excel (Microsoft, Red-
mond, Washington, United States). Proportional out-
comes were pooled using random effects model and
DerSimonian-Laird Method. Risk ratio (RR) with 95%
confidence interval (CI) was calculated for each outcome.
A p-value of < 0.05 was considered statistically significant
when comparing outcomes. The fixed effect model was
utilized as a sensitivity tool. The I2 statistic was used to
test for heterogeneity between the studies as defined by
Cochrane handbook for systematic reviews. The I2 of
values of < 30, 30–60%, 61–75%, and > 75% were suggest-
ive of low, moderate, substantial, and considerable hetero-
geneity, respectively [18, 19]. [The outcomes were
generated using Open Meta Analyst (CEBM, University of
Oxford, Oxford, United Kingdom) and Review Manager
v5.3 (Cochrane Collaboration, London, United
Kingdom)].
Bias assessment
We used the Cochrane Risk of bias tools for RCTs and
Newcastle Ottawa score for cohort studies [18–20]. Pub-
lication bias was assessed using funnel plot generated on
Fig. 1 Flow diagram describing our data collection
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Review Manager (Cochrane Collaboration, London,
United Kingdom).
Results
Figure 1 highlights our data collection process. 302 stud-
ies were identified from database searches. After removal
of duplicates, 42 clinical trials and 57 chart reviews/core-
lative studies/basic science studies were assessed further.
18 studies met our criteria for including both somatic
and germline BRCA mutations and were assessed fur-
ther. Only 8 studies reported ORR for both somatic and
germline BRCA mutations.
Characteristics of included studies
Amongst the 18 studies that we identified that included
both somatic and germline BRCA mutations treated
with PARPi, 14 studies involved use of PARPi as mono-
therapy, whereas 4 involved use of PARPi in combin-
ation with other therapies. 6 studies evaluated PARPi in
a maintenance setting. Olaparib was studied in 7 [21–
27], rucaparib in 4 [28–31], niraparib in 3 [32–34], and
talazoparib in 2 studies [35, 36] respectively. 10 of the
studies were for ovarian cancer patients, 2 for pancreatic
cancer, 3 for prostate cancer, 2 for multiple solid tu-
mors, and 1 for cholangiocarcinoma respectively.
Across all 18 studies, a total of 236 patients with som-
atic BRCA mutations were treated with PARPi, and 1204
patients with germline BRCA mutations were treated
with PARPi. When accounting for only the monotherapy
PARPi studies, there were 196 somatic and 1044 germ-
line patients.
Overall response rate data
A total of eight studies described ORR data for both
somatic and germline patients separately in either the
abstract, manuscript or appendix. Table 1 includes data
on these studies.
Within the eight studies for the patients for which
ORR was clearly evaluated, 43 patients with somatic
BRCA mutations received PARPi, and 157 patients with
germline BRCA patients received PARPi. 24 out of 43
patients with somatic BRCA mutations (55.8%), and 69
out of 157 (43.9%) patients with germline BRCA patients
had a response to therapy to PARPi. This difference was
not statistically significant (pooled OR 1.13 with 95%CI
0.85–1.49, p value = 0.399, I2 = 0) (Fig. 2).
Subgroup analysis was done to determine any differ-
ence in ORR amongst different groups listed below be-
tween somatic versus germline BRCA.
Cancer type
Amongst the eight studies that reported ORR, 2 studies
each were exclusively for prostate cancer, ovarian cancer
and pancreatic cancer, whereas 2 studies recruited pa-
tients with various malignancies.
Amongst the two studies for prostate cancer (Abida
et al.31 and Mateo et al.26), the pooled response was 10/
16 for somatic BRCA patients (62.5%), and 8/13 (61.5%)
for germline BRCA patients (p = 0.92).
Amongst the two studies for pancreatic cancer (Binder
et al.28 and Shroff et al.29), the pooled response was 3/4
for somatic BRCA patients (75%) and 7/32 (21.9%) for
germline BRCA patients, with the numerically increased
response rate in somatic BRCA patients not statistically
significant (p = 0.12).
Amongst the two studies for ovarian cancer (Konstan-
tinopaulos et al. [22] and Oza et al.30), the pooled re-
sponse rate was 11/22 for somatic BRCA patients (50%)
and 50/98 (51%) for germline BRCA patients (p = 0.84).
Type of PARPi
Amongst the eight studies that reported ORR, 4 studies
evaluated rucaparib and 2 studies evaluated olaparib,
with 2 studies evaluating talazoparib. As the 2 studies
that evaluated talazoparib had only 1 somatic BRCA pa-
tient each, a further subset analysis for talazoparib was
not conducted [35, 36].
Amongst the 4 studies using rucaparib, the pooled re-
sponse rate was 19/34 (55.9%) for somatic BRCA pa-
tients and 59/130 (45.4%) for germline BRCA patients
(p = 0.27).
Amongst the 2 studies evaluating olaparib, the pooled
response rate was 5/7 (71.4%) for somatic BRCA patients
and 6/13 (46.1%) for germline BRCA patients (p = 0.88).
Combination with other agents versus PARPi
monotherapy
As other agents used with PARPi could influence re-
sponse, we also assessed for PARPi monotherapy studies
versus PARPi combination studies.
Amongst the 6 studies that used PARPi as monother-
apy, the pooled response rate was 23/39 (58.9%) for
somatic BRCA patients and 63/140 (45%) for germline
BRCA patients (p = 0.35).
Amongst the 2 studies that used PARPi in combin-
ation with other agents, the pooled response rate was 1/
4 (25%) for somatic BRCA patients and 6/17 (35.3%) for
germline BRCA patients (p = 0.35).
Publication Bias
Funnel plot represented below (Fig. 3) represented vis-
ible asymmetry for published studies signifying a signifi-
cant publication bias. Supplementary Table S2 highlights
risk of bias for each study.
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Progression-free survival data
Only a total of five studies clearly described PFS data for
both somatic and germline BRCA patients (Table 2).
This amounted to a total of 111 patients with somatic
mutations and 569 patients with germline BRCA
mutations.
The PFS data was presented in a heterogenous and
non-uniform way limiting a meta-analysis. Table 2 in-
dicates PFS data for the five studies. In all five stud-
ies, there was no obvious difference in outcomes
between somatic versus germline BRCA patients,
however a precise statistical analysis could not be
performed.
Discussion
The PARPi are a novel drug group that inhibit the activ-
ity of PARP1, PARP2 and PARP3, a group of proteins
closely involved in the repair of single strand DNA
strand breaks [11]. When these molecules are inhibited,
the BRCA-mutated cells are unable to undergo the sig-
nificant homologous recombination or DNA strand re-
pair needed to fix the errors, effectively leading to arrest
during the cell replication cycle, and eventually to apop-
tosis [12, 13]. With further characterization of BRCA
mutations and development of more PARPi, therapeutic
options for individuals with advanced ovarian cancers as
well as certain breast cancers are increasing, with
Fig. 2 Forest plot representing comparison of response rate between somatic versus germline BRCA mutations (CI: Confidence interval)
Fig. 3 Funnel plot showing visible asymmetry for published studies
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expanded use of these drugs currently undergoing inves-
tigation [14, 38]. Olaparib subsequently gained approval
in metastatic breast cancer with germline BRCA muta-
tions based on the OlympiAD trial in 2017 [38], nira-
parib gained approval as maintenance treatment for
patients with ovarian cancer who are responding to
platinum-based chemotherapy in 2017 based on the
NOVA trial [33], and talazoparib was also approved in
2018 for advanced breast cancer with germline BRCA
mutations [39].
Germline mutations of BRCA1 and BRCA2 are signifi-
cantly associated with the development of multiple neo-
plasms, including breast, ovarian, stomach, pancreas,
colon, and melanoma [3–5]. However somatic BRCA
mutations are under-recognized and represent a missed
opportunity for further targeted therapy [6]. Many of the
existing clinical trials for the PARPi don’t specifically in-
clude somatic BRCA patients, leading to underrepresen-
tation in the data. The initial clinical trial, Study 42,
leading to FDA approval for olaparib in advanced ovar-
ian cancer, only examined germline BRCA mutations
[40]. The OlympiAD phase III trial for olaparib in breast
cancer by Robson et al. required a deleterious or sus-
pected deleterious germline BRCA mutation for eligibil-
ity [38]. The phase III trial for talazoparib in advanced
breast cancer by Litton et al. included only germline mu-
tation in BRCA1/2 as well [39]. The recent POLO trial
for pancreatic cancer which studied olaparib as mainten-
ance therapy also did not include any somatic BRCA pa-
tients [41].
Exclusion of such patients from clinical trials has
thus led to a lack of data of efficacy of PARPi in this
subgroup. Furthermore, given concerns over whether
somatic BRCA mutations are passenger or driver mu-
tations, further data is needed to establish efficacy in
this setting [15]. A potential expansion of the indica-
tion of approved medications for germline BRCA to
somatic BRCA can provide care to a greater number
of patients [6, 8–10].
Our data demonstrates a comparable ORR of PARPi
in somatic and germline BRCA patients. A subgroup
analyses accounting for different malignancy types and
different PARPi also did not reveal any significant differ-
ence in response rates. Although we were unable to per-
form a meta-analysis of PFS data, the reviewed literature
indicates similar efficacy of PARPi between somatic ver-
sus germline BRCA in terms of PFS. Our data indicates
that broader testing for somatic BRCA mutations should
be considered.
Our study was limited by inconsistent reporting of
PFS and ORR. The heterogeneity of the setting of use
for PARPi in the studies included may limit
generalizability as well, as in some studies the PARPi
was used for maintenance therapy and in others for later
lines of treatment.
Furthermore, we could not include several significant
publications in our analysis due to exclusion of either
somatic of germline BRCA patients, or no clear report-
ing of outcome specifically for each subgroup. For ex-
ample, the POLO trial studying olaparib for pancreatic
cancer did not include somatic BRCA patients and could
not be included [41]. Conversely, the PROFOUND trial
in prostate cancer which is looking at the efficacy of
PARPi in patients with an array of somatic mutations in-
volved in homologous recombination repair pathways
does not include any germline mutation patients, and
could not be included in our study [42]. Some studies
are known to have included both somatic and germline
patients, but do to a lack of subset analysis reported spe-
cifically for somatic BRCA patients, they could not be
included for analysis, such as the QUADRA study [32].
Our study is the first to review all currently published
data to compare ORR between somatic BRCA mutations
and germline BRCA mutations when treated with a
PARPi. Our analyses revealed a similar ORR between
both cohorts. Our data would suggest that broader indi-
cations for PARPi therapy may be considered. Further-
more, our data supports the inclusion of somatic BRCA
Table 2 Progression-Free Survival (PFS) data for somatic versus germline BRCA mutations
Study Name PFS for somatic BRCA PFS for germline BRCA Statistical difference between somatic versus
germline
ARIEL3 [21] HR of 0.23 (0.10–0.54)
compared to placebo,
Median PFS 15.7 months






HR of 0.27 compared to
placebo
HR of 0.27 compared to placebo Not provided
STUDY 19 [23] HR of 0.23 (0.04 to 1.12) versus
placebo,
3/10 progression events






Absolute value not reported Absolute value not reported HR of 0.75 for PFS (0.4–1.41) between somatic
versus germline, p = 0.38
Labidy-Galy et al. [27] 6.8 months (5.1-NA)
Median PFS
16.3 (10.4–19.8) median PFS HR of 1.4 (0.5–3.9), p = 0.52
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patients in future clinical trials for PARPi therapy. An
example of such a study is the NIRAPANC trial enrol-
ling metastatic pancreatic cancer patients with somatic
and germline BRCA mutations, as well as other DNA re-
pair deficiencies [43]. Notably in the COVID-19 era,
PARP inhibitors, due to its per oral administration, has
the added advantage of limiting patient in person health-
care visits and associated exposure, for instance com-
pared to intravenously administered anti-cancer agents,
especially with the availability of telemedicine follow-up.
Conclusion
The use of PARPi in BRCA-related malignancy have
largely been limited to BRCA germline mutations, and
thus a precise estimate of efficacy of PARPi in somatic
BRCA mutation in lacking. Our meta-analysis and sys-
tematic review of the literature indicates similar re-
sponse rates of PARPi therapy in patients with somatic
and germline BRCA mutations. Investigation of use of
PARPi therapy in a broader patient population, and the
inclusion of patients with somatic BRCA mutations in
further clinical trials is paramount in improving thera-
peutic options for our patients.
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